Lazar David E. 13D and 13G filings for Cyclacel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-28 4:46 pm Purchase |
2025-02-06 | 13D | Cyclacel Pharmaceuticals, Inc. CYCC |
Lazar David E. | 39,021,180 15.840% |
39,021,180 (New Position) |
Filing |